Author： Yan Ying Silvennoinen-Kassinen Sylvi Leinonen Maija Saikku Pekka
Publisher： Springer Publishing Company
ISSN： 0920-3206
Source： Cardiovascular Drugs and Therapy, Vol.24, Iss.3, 2010-06, pp. : 189-195
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
High-dose valsartan for prevention of in-stent restenosis
Inpharma, Vol. 1, Iss. 1637, 2008-01 ,pp. :
Access to resources
Recommend
Usefulness of Sparfloxacin against
By Horiguchi T Miyazaki J Ohira D Watanabe Y Hayashi N Kobayashi K Torigoe T Fukumoto K Ito T Hirose M Sasaki Y Shiga M Kondo R Handa M Tachikawa S
The Journal of International Medical Research, Vol. 33, Iss. 6, 2005-11 ,pp. :
By Villegas Enrique Camacho Ana Carrillo Jose Antonio Sorlózano Antonio Rojas José Gutiérrez José
Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 10, 2008-10 ,pp. :
Rosiglitazone reduces in-stent restenosis in patients with diabetes
Inpharma, Vol. 1, Iss. 1462, 2004-01 ,pp. :
Candesartan cilexetil may reduce in-stent restenosis
Inpharma, Vol. 1, Iss. 1476, 2005-01 ,pp. :